# Phase 1 glioma trials recruiting: 68 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 68 trials in phase 1 for glioma that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1 glioma trials: 68 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1/glioma

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 68
- Recruiting or not yet: 68
- Read on: November 19, 2026

## Trials

The 25 newest of 68, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 10, 2026 | NCT07929909 | A Phase I Clinical Study of YN003 in the Treatment of Glioma | Beijing Inno Medicine Co., Ltd. | Phase 1 | Recruiting | Glioma, Glioblastoma, Brain Neoplasms | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07929909) |
| September 18, 2026 | NCT07826949 | A Study of SRN-101 Administered Prior to Surgical Resection in Adults With Recurrent High-Grade Glioma. | Sponsor not shown (see the record) | Phase 1 | Not yet recruiting | Recurrent High-Grade Gliomas, Brain Neoplasm, Glioma | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07826949) |
| August 27, 2026 | NCT07791264 | FPS-ZM1 With or Without Dexamethasone for Controlling Post Operative Cerebral Edema in Patients With Glioblastoma | City of Hope Medical Center | Phase 1 | Not yet recruiting | Glioblastoma, Malignant Glioma, Recurrent Glioblastoma, Recurrent Malignant Glioma | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07791264) |
| August 26, 2026 | NCT07788677 | Tarlatamab Treatment Before and After Surgery in Surgically Resectable Recurrent High-grade Glioma: a Window of Opportunity Study... | Vall d'Hebron Institute of Oncology | Phase 1 | Not yet recruiting | High-Grade Glioma (HGG) | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07788677) |
| July 29, 2026 | NCT07733674 | Study of 203Pb-RMX-VH-PIB Dosimetry and Biodistribution in Patients With Glioblastoma Multiform (GBM) and Pancreatic Ductal Adenocarcinoma... | Radiomedix, Inc. | Phase 1 | Recruiting | Glioblastoma Multiforme (GBM), Pancreatic Ductal Adenocarcinoma (PDAC) | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07733674) |
| July 17, 2026 | NCT07710690 | A Clinical Trial Evaluating the Tolerability, Safety, and Preliminary Efficacy of NRG-103 Injection in Patients With Recurrent or... | Neuregen Therapeutics Co., Ltd. | Phase 1 | Recruiting | HGG, High Grade Glioma (III or IV), High Grade Glioma | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07710690) |
| June 24, 2026 | NCT07664176 | NgFUS NIVO: NeuroNavigation-Guided Focused Ultrasound With Nivolumab in Relapsed and Progressive DMG and Other High Grade Brain Tumors | Children's National Research Institute | Phase 1 | Recruiting | Diffuse Midline Glioma or Diffuse Intrinsic Pontine Glioma, High Grade Gliomas, Medulloblastoma Recurrent, Ependymoma... | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07664176) |
| June 5, 2026 | NCT07629089 | VorAsidenib With Lomustine In Patients With rEcurrent IDH-mutaNT Glioma Harboring IDH1 and/or IDH2 Mutations | Sponsor not shown (see the record) | Phase 1 | Not yet recruiting | Recurrent Glioma, IDH-mutant Gliomas | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07629089) |
| April 24, 2026 | NCT07551336 | Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma | Beijing Biotech | Phase 1 | Recruiting | Malignant Glioma, High-Grade Gliomas, Glioblastoma, Recurrent High-Grade Gliomas, Recurrent Glioblastoma | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07551336) |
| April 21, 2026 | NCT07541781 | Sitagliptin in Recurrent/Progressive Grade 4 Glioma | Sponsor not shown (see the record) | Phase 1 | Recruiting | Glioma, Glioblastoma, Recurrent Glioma, Recurrent Glioblastoma, Grade 4 Malignant Glioma of Brain (Disorder) | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07541781) |
| March 19, 2026 | NCT07481721 | IL13Rα2 CAR-T Cells Secreting Anti-PD-L1 Antibody for Recurrent Malignant Glioma | Sponsor not shown (see the record) | Phase 1 | Not yet recruiting | Recurrent Malignant Glioma | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07481721) |
| March 18, 2026 | NCT07480941 | Dual-Targeting CAR-NK Cell Therapy for Recurrent/Progressive Glioblastoma and High-Grade Glioma | Beijing Biotech | Phase 1 | Recruiting | Glioblastoma, High-grade Glioma, Malignant Glioma, Recurrent Glioblastoma, Recurrent High-grade Glioma | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07480941) |
| March 16, 2026 | NCT07472790 | A Study on the Novel Oncolytic Virus Combined With PD-1 Inhibitor in the Treatment of Recurrent High-grade Glioma | Beijing Bio-Targeting Therapeutics Technology Co., Ltd | Phase 1 | Not yet recruiting | High-grade Glioma | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07472790) |
| March 11, 2026 | NCT07464925 | A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma | Tetragon Biosciences Ltd | Phase 1 | Recruiting | Glioblastoma Multiforme of Brain, Glioma, Glioblastoma | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07464925) |
| March 9, 2026 | NCT07457307 | Integrating Biology for Safe Intensification of Glioblastoma Hypofractionated Treatment on the MR-Linac | NYU Langone Health | Phase 1 | Not yet recruiting | High-grade Glioma | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07457307) |
| March 6, 2026 | NCT07455045 | A Phase I Study of FZ-AD005 in Patients With High-Grade Glioma (HGG) | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Phase 1 | Not yet recruiting | High Grade Glioma (III or IV), Diffuse Midline Glioma (DMG), Glioblastoma (GBM) | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07455045) |
| February 27, 2026 | NCT07438860 | Fluorescence-Guided Imaging of Brain Tumors: A Safety Study Using SBK2-ICG | Sponsor not shown (see the record) | Phase 1 | Not yet recruiting | Malignant Brain Tumors, Glioma | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07438860) |
| January 9, 2026 | NCT07331064 | Gallium Maltolate for the Treatment of Pediatric Patients With Relapsed or Refractory Pediatric High-Grade Glioma and Atypical Teratoid... | Sponsor not shown (see the record) | Phase 1 | Not yet recruiting | High Grade Gliomas, Atypical Teratoid Rhabdoid Tumors (ATRT), Diffuse Midline Glioma, DIPG, Diffuse Intrinsic Pontine... | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07331064) |
| December 29, 2025 | NCT07306299 | A Phase I Clinical Trial of a mRNA Vaccine for Recurrent or Progressive High-grade Glioma | Second Affiliated Hospital, Zhejiang University, School of Medicine | Phase 1 | Recruiting | Glioma, High Grade | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07306299) |
| October 31, 2025 | NCT07223034 | A Study of 177Lu-PSMA-617 in People With Gliomas | Memorial Sloan Kettering Cancer Center | Phase 1 | Recruiting | Glioma, Diffuse Astrocytoma, IDH-Wildtype (Grade 2-4), Glioblastoma, IDH-wildtype, Diffuse Midline Glioma, H3... | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07223034) |
| October 20, 2025 | NCT07218367 | Phase I Trial of pH Resections of GBM at VA | VA Office of Research and Development | Phase 1 | Not yet recruiting | Glioblastoma | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07218367) |
| September 17, 2025 | NCT07179328 | Focused Ultrasound Blood-Brain Barrier Disruption for the Treatment of High-Grade Glioma in Patients Undergoing Standard Chemotherapy | Sunnybrook Health Sciences Centre | Phase 1 | Recruiting | GBM, Glioblastoma Multiforme (GBM), Glioblastoma Multiforme of Brain, Glioblastoma Multiforme Glioma, HGG, Glioma... | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07179328) |
| July 22, 2025 | NCT07076498 | Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standard of Care Radiation | M.D. Anderson Cancer Center | Phase 1 | Recruiting | Glioma | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07076498) |
| June 17, 2025 | NCT07025018 | Phase I Study of HMPL-306 for the Treatment of Gliomas With IDH1 and/or IDH2 Mutations | Hutchmed | Phase 1 | Recruiting | Gliomas Harboring IDH1 and/or IDH2 Mutations | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07025018) |
| May 9, 2025 | NCT06964737 | Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas | Ohio State University Comprehensive Cancer Center | Phase 1 | Recruiting | Recurrent Malignant Glioma, Recurrent WHO Grade 3 Glioma, Recurrent WHO Grade 4 Glioma, WHO Grade 2 Glioma, WHO Grade 3... | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06964737) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| M.D. Anderson Cancer Center | 3 |
| University of Florida | 3 |
| Capital Medical University | 2 |
| [Beijing Biotech](https://specstream.ai/data/clinical-trials/company/beijing-biotech) | 2 |
| Shenzhen Geno-Immune Medical Institute | 1 |
| Assistance Publique - Hôpitaux de Paris | 1 |
| Suzhou Maximum Bio-tech Co., Ltd. | 1 |
| Neuregen Therapeutics Co., Ltd. | 1 |
| University of Maryland, Baltimore | 1 |
| Vall d'Hebron Institute of Oncology | 1 |
| Nationwide Children's Hospital | 1 |
| Case Comprehensive Cancer Center | 1 |
| OX2 Therapeutics | 1 |
| University of California, San Francisco | 1 |
| Radiomedix, Inc. | 1 |
| Children's National Research Institute | 1 |
| Tcelltech Inc. | 1 |
| Columbia University | 1 |
| Memorial Sloan Kettering Cancer Center | 1 |
| Baylor College of Medicine | 1 |
| Beijing Bio-Targeting Therapeutics Technology Co., Ltd | 1 |
| [Sichuan Baili Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/sichuan-baili-pharmaceutical-co-ltd) | 1 |
| University of Miami | 1 |
| Henry Ford Health System | 1 |
| Chulalongkorn University | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 48 |
| China | 16 |
| Spain | 2 |
| France | 1 |
| Thailand | 1 |
| Australia | 1 |
| Austria | 1 |
| Germany | 1 |
| Netherlands | 1 |
| Switzerland | 1 |
| Canada | 1 |
| Italy | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Land surveyors in the United States](https://specstream.ai/data/businesses/land-surveyors/united-states)
- [Paralegal companies in the United States](https://specstream.ai/data/businesses/paralegal-companies/united-states)
- [Scale suppliers in the United States](https://specstream.ai/data/businesses/scale-suppliers/united-states)
- [Valet services in the United States](https://specstream.ai/data/businesses/valet-services/united-states)
- [B2B equipment maintenance and repair companies in the United States](https://specstream.ai/data/businesses/b2b-equipment-maintenance-and-repair-companies/united-states)
- [Chiropractic clinics in the United States](https://specstream.ai/data/businesses/chiropractic-clinics/united-states)
